|
Adenocarcinoma
|
0.070 |
GeneticVariation
|
group |
BEFREE |
The development of adenocarcinoma of the lung is believed to proceed from in situ disease (adenocarcinoma in situ, AIS) to minimally invasive disease with prominent lepidic growth (minimally invasive adenocarcinoma, MIA), then to fully invasive adenocarcinoma (AD), but direct evidence for this model has been lacking.
|
24879567 |
2014 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
MIA PaCa-2 pancreatic head exocrine adenocarcinoma cells (mutant p53) were treated by mock infection or adenoviruses expressing beta-galactosidase or E2F-1 (Ad-E2F-1) alone or in combination with sublethal concentrations of each chemotherapeutic drug.
|
12065845 |
2002 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
A higher SUVmax can be expected in invasive adenocarcinoma than in MIA, and solid and acinar-predominant invasive adenocarcinoma showed a higher SUVmax.
|
29127699 |
2018 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
To evaluate progressive changes in quantitative CT features of the non-solid component of ground-glass nodules (GGNs) from baseline to follow-up to differentiate invasive (minimally invasive adenocarcinoma [MIA] and invasive adenocarcinoma [IA]) GGNs from benign or pre-invasive (adenocarcinoma in situ [AIS]) lesions.
|
29329732 |
2018 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
According to the clinical management strategies, cases were divided into pre-invasive and MIA groups (atypical adenomatous hyperplasia [AAH], adenocarcinoma in situ [AIS], and minimally invasive adenocarcinoma [MIA]) and invasive group (invasive adenocarcinoma [IAC]).
|
29397913 |
2018 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
Multivariable analysis showed that tumor invasion (invasive adenocarcinoma [IAD] vs adenocarcinoma in situ [AIS]/minimally invasive adenocarcinoma [MIA], p = 0.020) was the only independent predictor for 5-year LCS-RFS.
|
30096292 |
2018 |
|
Adenocarcinoma
|
0.070 |
Biomarker
|
group |
BEFREE |
To examine the diversity of somatic alterations and clonal evolution according to aggressiveness of disease, nineteen tumor-blood pairs of 'formerly bronchiolo-alveolar carcinoma (BAC)' which had been reclassified into preinvasive lesion (adenocarcinoma in situ; AIS), focal invasive lesion (minimally invasive adenocarcinoma; MIA), and invasive lesion (lepidic predominant adenocarcinoma; LPA and non-lepidic predominant adenocarcinoma; non-LPA) according to IASLC/ATS/ERS 2011 classification were explored by whole exome sequencing.
|
27545006 |
2016 |
|
Adenocarcinoma in Situ
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
To evaluate progressive changes in quantitative CT features of the non-solid component of ground-glass nodules (GGNs) from baseline to follow-up to differentiate invasive (minimally invasive adenocarcinoma [MIA] and invasive adenocarcinoma [IA]) GGNs from benign or pre-invasive (adenocarcinoma in situ [AIS]) lesions.
|
29329732 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
To elucidate the involvement of MK in the development of tumors, we further examined its expression in a variety of human neoplastic cell lines: YMB-1-C (breast cancer), EBC-1 (lung squamous cell carcinoma), RERF-LC-OK (lung adenocarcinoma), SBC-3 (lung small cell carcinoma), HSC-2 (mouth squamous cell carcinoma), NUGC-2 (gastric cancer), COLO201 (colon cancer), HepG2 (hepatoma), MIA PaCa-2 (pancreatic cancer), MCAS (ovarian cancer), HeLa (cervical cancer), BeWo (chorionic carcinoma), ITO-II (testicular tumor), T24 (urinary bladder tumor), and G-401 (Wilms' tumor).
|
8434639 |
1993 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
The development of adenocarcinoma of the lung is believed to proceed from in situ disease (adenocarcinoma in situ, AIS) to minimally invasive disease with prominent lepidic growth (minimally invasive adenocarcinoma, MIA), then to fully invasive adenocarcinoma (AD), but direct evidence for this model has been lacking.
|
24879567 |
2014 |
|
Adenocarcinoma of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
The full-length TF gene (1360 base pairs) was cloned into the plasmid DNA vector pcDNA3 in sense and antisense orientations, and these vectors were used to transfect the MIA PaCa-2 human pancreatic adenocarcinoma cell line.
|
10417560 |
1999 |
|
Adenomatous Polyposis Coli
|
0.010 |
Biomarker
|
disease |
BEFREE |
Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients.
|
28306719 |
2017 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that GHRH antagonists induce apoptosis through key proapoptotic pathways and shows the efficacy of MIA-602 for experimental treatment of glioblastoma.
|
20162575 |
2010 |
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Despite retention of the carboxylate and the ether bridgehead known to impart cytotoxic activity to norcantharidin, none of these analogues displayed notable cytotoxicity against the 11 cell lines examined: HT29 (colon), MCF-7 (breast), A2780 (ovarian), H460 (lung), A431 (skin), Du145 (prostate), BE2-C (neuroblastoma), SJ-G2 and U87 (glioblastoma), MIA (pancreatic), and SMA (spontaneous murine astrocytoma).
|
30938091 |
2019 |
|
Agnosia for Pain
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The first group (26 patients) received multi-site infiltration analgesia (MIA group), the second group (27 patients) received femoral nerve block (FNB group), and the third group (24 patients) received adductor cannel block (ACB group).
|
27557955 |
2017 |
|
AICARDI-GOUTIERES SYNDROME
|
0.010 |
Biomarker
|
disease |
BEFREE |
In this study we examined the expression of mRNA for GHRH and for SVs of its receptors in tumors of human pancreatic, colorectal, and gastric cancer cell lines grown in nude mice. mRNA for both GHRH and SV(1) isoform of GHRH receptors was expressed in tumors of pancreatic (SW1990, PANC-1, MIA PaCa-2, Capan-1, Capan-2, and CFPAC1), colonic (COLO 320DM and HT-29), and gastric (NCI-N87, HS746T, and AGS) cancer cell lines; mRNA for SV(2) was also present in Capan-1, Capan-2, CFPAC1, HT-29, and NCI-N87 tumors.
|
12186980 |
2002 |
|
AMYLOIDOSIS, HEREDITARY, TRANSTHYRETIN-RELATED
|
0.010 |
Biomarker
|
disease |
BEFREE |
Chromosome 19q13 disruption alters expressions of CYP2A7, MIA and MIA-RAB4B lncRNA and contributes to FAP-like phenotype in APC mutation-negative familial colorectal cancer patients.
|
28306719 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.060 |
Biomarker
|
disease |
BEFREE |
While no phenotypic changes were observed for MIA PaCa-2-passaged viruses, both SUIT-2-passaged VSV-p53wt and VSV-p53-CC showed improved replication in SUIT-2 and AsPC-1, another human PDAC cell line also moderately resistant to VSV, while remaining highly attenuated in non-malignant cells.
|
31694943 |
2020 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.060 |
Biomarker
|
disease |
BEFREE |
Moreover, the inhibitory effect of CXCR2 antagonist on PDAC cell proliferation was more powerful in MIA PaCa-2 cells than CFPAC-1 cells.
|
28214673 |
2017 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.060 |
Biomarker
|
disease |
BEFREE |
Treatment of PDAC cell lines BxPC-3 and MIA PaCa-2 with a specific HDAC inhibitor, trichostatin A (TSA), strongly activates TbetaRII promoter activity and induces TbetaRII expression.
|
12750289 |
2003 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.060 |
Biomarker
|
disease |
BEFREE |
The viability and proliferation of primary (PANC-1 and MIA PaCa-2) and metastatic (SW1990 and ASPC-1) PDAC cell lines treated with L48H37 was determined by CCK8 and colony formation assay.
|
31435462 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here, we assessed the sensitivities of BRCA2-deficient (Capan-1) and BRCA2-proficient (MIA PaCa-2) PDAC cell lines to a panel of DCLs and PARPis.
|
25864590 |
2015 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.060 |
Biomarker
|
disease |
BEFREE |
We combined data from miRNA and messenger RNA (mRNA) expression profiles and bioinformatic analyses to identify an miRNA-mRNA regulatory network in PDAC cell lines (PANC-1 and MIA PaCa-2) and in PDAC samples from patients.
|
24120476 |
2014 |
|
Anxiety
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Both groups also completed two scales of the MIA questionnaire (locus of control and anxiety) to identify potential predictors of memory performance.<b>Results</b>: Results indicated that the non-threatened group performed better than the threatened group on the episodic memory task.
|
31752597 |
2019 |
|
Anxiety Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Both groups also completed two scales of the MIA questionnaire (locus of control and anxiety) to identify potential predictors of memory performance.<b>Results</b>: Results indicated that the non-threatened group performed better than the threatened group on the episodic memory task.
|
31752597 |
2019 |